Starting Dose of Mounjaro for Weight Loss
The starting dose of Mounjaro (tirzepatide) for weight loss is 2.5 mg subcutaneously once weekly, which must be increased to 5 mg weekly after 4 weeks, as the 2.5 mg dose is for treatment initiation only and not intended for therapeutic effect. 1
Dosing Algorithm
Initial Phase (Weeks 0-4)
- Start at 2.5 mg subcutaneously once weekly
- This dose serves solely as a tolerability initiation phase to reduce gastrointestinal side effects
- It provides no meaningful weight loss benefit on its own
Escalation Phase (Week 4 onwards)
- Mandatory increase to 5 mg weekly at week 4
- Further dose escalation in 2.5 mg increments can occur every 4 weeks based on:
- Weight loss response
- Tolerability of gastrointestinal side effects
- Individual treatment goals
Maximum Doses
- Adults: 15 mg weekly 1
- Available doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg
Evidence-Based Weight Loss Expectations
Real-world and trial data demonstrate dose-dependent weight loss:
- 5 mg weekly: Mean 15.0% body weight reduction at 72 weeks 2
- 10 mg weekly: Mean 19.5% body weight reduction at 72 weeks 2
- 15 mg weekly: Mean 20.9% body weight reduction at 72 weeks 2
Recent real-world evidence shows that even low-to-moderate doses (predominantly 5 mg) achieve clinically meaningful results, with 94.2% of patients achieving ≥5% weight loss and 77.9% achieving ≥10% weight loss at 6 months 3.
Critical Clinical Considerations
FDA Indication Caveat
While the FDA label specifies Mounjaro is indicated for type 2 diabetes mellitus 1, clinical guidelines now support its use for obesity. The 2025 BMJ guideline provides a weak recommendation in favor of tirzepatide for adults with obesity, acknowledging superior weight loss compared to GLP-1 receptor agonists but noting lower certainty evidence for cardiovascular and kidney outcomes 4.
Gastrointestinal Tolerability
The gradual dose escalation protocol is essential—gastrointestinal adverse events (nausea, vomiting, diarrhea) are the most common side effects, occurring primarily during dose escalation. These are typically mild-to-moderate and improve with time 2, 3. Treatment discontinuation due to adverse events ranges from 4.3% at 5 mg to 7.1% at 10 mg 2.
Long-Term Maintenance
Evidence from SURMOUNT-MAINTAIN demonstrates that continuing tirzepatide at maximum tolerated dose maintains weight loss, while dose reduction to 5 mg still provides benefit superior to discontinuation 5. This supports the need for ongoing therapy rather than time-limited treatment.
Contraindications
Do not use in patients with:
- Personal or family history of medullary thyroid carcinoma
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) 1
Administration Specifics
- Inject subcutaneously in abdomen, thigh, or upper arm
- Can be given any time of day, with or without meals
- If a dose is missed, administer within 4 days; if >4 days have passed, skip and resume regular schedule 1